NASDAQ: PMVPPmv Pharmaceuticals Inc Stock
$5.49+0.04 (+0.73%)
Updated Mar 20, 2023
PMVP Price
$5.49
Fair Value Price
$7.88
Market Cap
$251.30M
52 Week Low
$5.09
52 Week High
$24.27
P/E
-3.41x
P/B
1.02x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$73.32M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.1
Operating Cash Flow
-$64M
Beta
1.41
Next Earnings
May 8, 2023
Ex-Dividend
N/A
Next Dividend
N/A
PMVP Overview
PMV Pharmaceuticals, Inc. is developing small molecule and tumor-agnostic therapies for p53 mutations in cancer. Formerly PJ Pharmaceuticals, Inc., the company was incorporated in 2013 and is headquartered in Cranbury, NJ.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PMVP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PMVP ($5.49) is undervalued by 30.34% relative to our estimate of its Fair Value price of $7.88 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
PMVP ($5.49) is significantly undervalued by 30.34% relative to our estimate of its Fair Value price of $7.88 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
PMVP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PMVP due diligence checks available for Premium users.
Be the first to know about important PMVP news, forecast changes, insider trades & much more!
PMVP News
Valuation
PMVP fair value
Fair Value of PMVP stock based on Discounted Cash Flow (DCF)
Price
$5.49
Fair Value
$7.88
Undervalued by
30.34%
PMVP ($5.49) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PMVP ($5.49) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PMVP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PMVP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.41x
Industry
16.1x
Market
22.37x
PMVP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.02x
Industry
4.81x
PMVP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PMVP's financial health
Profit margin
Revenue
$0.0
Net Income
-$19.3M
Profit Margin
0%
PMVP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$270.3M
Liabilities
$24.3M
Debt to equity
0.1
PMVP's short-term assets ($247.01M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PMVP's short-term assets ($247.01M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PMVP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$15.3M
Investing
$23.2M
Financing
$548.0k
PMVP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PMVP vs Biotech Stocks
Pmv Pharmaceuticals Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.